Evidence map›Paper›PMID 39609309›Full record

ArticleFamilial cancer2024

Sarcomas arising in MEN1 patients: demonstrating LOH of the MEN1 locus and loss of menin expression.

Rachel S van Leeuwaarde, Thorvardur R Halfdanarson, Shwetha M Sudhakar, Ruud W J Meijers, Andrew L Folpe, Lodewijk A A Brosens

Abstract read
PubMed Publisher
In one paragraph

Article in Familial cancer, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Rachel S van LeeuwaardeDepartment of Endocrine Oncology, University Medical Center Utrecht, Heidelberglaan 100, Utrecht, 3584 CX, The Netherlands. r.vanleeuwaarde@umcutrecht.nl.
Thorvardur R HalfdanarsonDivision of Medical Oncology, Department of Oncology, Mayo Clinic, Rochester, MN, USA.
Shwetha M SudhakarDepartment of Endocrine Oncology, Levine Cancer Institute, Atrium Health, Charlotte, NC, USA.
Ruud W J MeijersDepartment of Pathology, Erasmus MC Cancer Institute, Rotterdam, the Netherlands.
Andrew L FolpeDepartment of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, 55905, USA.
Lodewijk A A BrosensDepartment of Pathology, UMC Utrecht, Utrecht University, Utrecht, The Netherlands.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Multiple endocrine neoplasia type 1 (MEN1) is a hereditary tumor syndrome characterized by endocrine tumors, typically from parathyroid, pancreatic, or anterior pituitary origin. In addition, benign cutaneous soft tissue tumors are prevalent in MEN1 patients. Although sarcomas have been reported in MEN1 patients it is unclear if these tumors should be considered as part of the MEN1 syndrome. Here, five patients with a MEN1 syndrome and a sarcoma are described. In all five sarcomas loss of heterozygosity of the MEN1 gene and loss of expression of menin are shown, suggesting that sarcomas may be a phenotypic expression of MEN1 syndrome.

Indexed as

Loss of HeterozygosityMultiple Endocrine Neoplasia Type 1Proto-Oncogene ProteinsSarcomaHumansMEN1 protein, humanProto-Oncogene ProteinsMEN1 geneMultiple Endocrine Neoplasia Type 1Sarcoma

Identifiers

PMID39609309

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.